国际肿瘤学杂志››2023,Vol. 50››Issue (4): 241-243.doi:10.3760/cma.j.cn371439-20230120-00047
李佳璇1, 封颖璐2(
)
收稿日期:2023-01-20修回日期:2023-03-06出版日期:2023-04-08发布日期:2023-06-12通讯作者:封颖璐，Email：
基金资助:
Li Jiaxuan1, Feng Yinglu2()
Received:2023-01-20Revised:2023-03-06Online:2023-04-08Published:2023-06-12Contact:Feng Yinglu， Email：
Supported by:
摘要：
糖皮质激素受体（GR）在癌细胞的信号转导、相关基因表达及凋亡中发挥十分关键的作用。肝癌具有侵袭性强、死亡率高的特征，在关于GR与肝癌关系的探索中，大量研究表明GR对肝癌细胞的生长有抑制作用，这为临床治疗肝癌提供了新思路和新方法。
李佳璇, 封颖璐. 糖皮质激素受体在肝癌细胞生长中的作用机制[J]. 国际肿瘤学杂志, 2023, 50(4): 241-243.
Li Jiaxuan, Feng Yinglu. Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells[J]. Journal of International Oncology, 2023, 50(4): 241-243.
| [1] | Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi:10.3322/caac.21660 |
| [2] | Meijer OC, Koorneef LL, Kroon J. Glucocorticoid receptor modulators[J]. Ann Endocrinol (Paris), 2018, 79(3): 107-111. DOI: 10.1016/j.ando.2018.03.004. doi:S0003-4266(18)30029-5pmid:29731108 |
| [3] | Kalfeist L, Galland L, Ledys F, et al. Impact of glucocorticoid use in oncology in the immunotherapy era[J]. Cells, 2022, 11(5): 770. DOI: 10.3390/cells11050770. doi:10.3390/cells11050770 |
| [4] | Caratti B, Fidan M, Caratti G, et al. The glucocorticoid receptor associates with RAS complexes to inhibit cell proliferation and tumor growth[J]. Sci Signal, 2022, 15(726): eabm4452. DOI: 10.1126/scisignal.abm4452. doi:10.1126/scisignal.abm4452 |
| [5] | Vesting AJ, Jais A, Klemm P, et al. NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibition[J]. Mol Metab, 2022, 66: 101626. DOI: 10.1016/j.molmet.2022.101626. doi:10.1016/j.molmet.2022.101626 |
| [6] | Whirledge S, DeFranco DB. Glucocorticoid signaling in health and disease: insights from tissue-specific GR knockout mice[J]. Endocrinology, 2018, 159(1): 46-64. DOI: 10.1210/en.2017-00728. doi:10.1210/en.2017-00728pmid:29029225 |
| [7] | Matthews LC, Berry AA, Morgan DJ, et al. Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy[J]. Proc Natl Acad Sci U S A, 2015, 112(17): 5479-5484. DOI: 10.1073/pnas.1411356112. doi:10.1073/pnas.1411356112 |
| [8] | Prekovic S, Schuurman K, Mayayo-Peralta I, et al. Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer[J]. Nat Commun, 2021, 12(1): 4360. DOI: 10.1038/s41467-021-24537-3. doi:10.1038/s41467-021-24537-3pmid:34272384 |
| [9] | Jiang Z, Zhang C, Liu X, et al. Dexamethasone inhibits stemness maintenance and enhances chemosensitivity of hepatocellular carcinoma stem cells by inducing deSUMOylation of HIF‑1α and Oct4[J]. Int J Oncol, 2020, 57(3): 780-790. DOI: 10.3892/ijo.2020.5097. doi:10.3892/ijo.2020.5097pmid:32705164 |
| [10] | Escoter-Torres L, Caratti G, Mechtidou A, et al. Fighting the fire: mechanisms of inflammatory gene regulation by the glucocorticoid receptor[J]. Front Immunol, 2019, 10: 1859. DOI: 10.3389/fimmu.2019.01859. doi:10.3389/fimmu.2019.01859pmid:31440248 |
| [11] | Timmermans S, Vandewalle J, Libert C. Dimerization of the glucocorticoid receptor and its importance in (patho)physiology: a primer[J]. Cells, 2022, 11(4): 683. DOI: 10.3390/cells11040683. doi:10.3390/cells11040683 |
| [12] | Morse MA, Sun W, Kim R, et al. The role of angiogenesis in hepatocellular carcinoma[J]. Clin Cancer Res, 2019, 25(3): 912-920. DOI: 10.1158/1078-0432.CCR-18-1254. doi:10.1158/1078-0432.CCR-18-1254pmid:30274981 |
| [13] | 朱金霞, 刘光伟, 杨培伟. 中医药调控Wnt/β-catenin通路治疗肝细胞癌的研究进展[J]. 中国中医基础医学杂志, 2023, 29(4): 679-686. DOI: 10.19945/j.cnki.issn.1006-3250.2023.04.011. doi:10.19945/j.cnki.issn.1006-3250.2023.04.011 |
| [14] | Liu B, Zhou H, Zhang T, et al. Loss of endothelial glucocorticoid receptor promotes angiogenesis via upregulation of Wnt/β-catenin pathway[J]. Angiogenesis, 2021, 24(3): 631-645. DOI: 10.1007/s10456-021-09773-x. doi:10.1007/s10456-021-09773-xpmid:33650028 |
| [15] | Marchi D, van Eeden FJM. Homeostatic regulation of glucocorticoid receptor activity by hypoxia-inducible factor 1: from physiology to clinic[J]. Cells, 2021, 10(12): 3441. DOI: 10.3390/cells10123441. doi:10.3390/cells10123441 |
| [16] | Tian H, Zhu X, Lv Y, et al. Glucometabolic reprogramming in the hepatocellular carcinoma microenvironment: cause and effect[J]. Cancer Manag Res, 2020, 12: 5957-5974. DOI: 10.2147/CMAR.S258196. doi:10.2147/CMAR.S258196pmid:32765096 |
| [17] | Greulich F, Hemmer MC, Rollins DA, et al. There goes the neighborhood: assembly of transcriptional complexes during the regulation of metabolism and inflammation by the glucocorticoid receptor[J]. Steroids, 2016, 114: 7-15. DOI: 10.1016/j.steroids.2016.05.003. doi:S0039-128X(16)30035-6pmid:27192428 |
| [18] | Ma R, Zhang W, Tang K, et al. Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma[J]. Nat Commun, 2013, 4: 2508. DOI: 10.1038/ncomms3508. doi:10.1038/ncomms3508pmid:24149070 |
| [19] | Cho JH, Lee YM, Starost MF, et al. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ⅰa at the tumor-developing stage[J]. J Inherit Metab Dis, 2019, 42(3): 459-469. DOI: 10.1002/jimd.12056. doi:10.1002/jimd.12056 |
| [20] | Feng J, Li J, Wu L, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2020, 39(1): 126. DOI: 10.1186/s13046-020-01629-4. doi:10.1186/s13046-020-01629-4 |
| [21] | Du D, Liu C, Qin M, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma[J]. Acta Pharm Sin B, 2022, 12(2): 558-580. DOI: 10.1016/j.apsb.2021.09.019. doi:10.1016/j.apsb.2021.09.019pmid:35256934 |
| [22] | Gnocchi D, Sabbà C, Massimi M, et al. Metabolism as a new avenue for hepatocellular carcinoma therapy[J]. Int J Mol Sci, 2023, 24(4): 3710. DOI: 10.3390/ijms24043710. doi:10.3390/ijms24043710 |
| [23] | Xu L, Xia H, Ni D, et al. High-dose dexamethasone manipulates the tumor microenvironment and internal metabolic pathways in anti-tumor progression[J]. Int J Mol Sci, 2020, 21(5): 1846. DOI: 10.3390/ijms21051846. doi:10.3390/ijms21051846 |
| [24] | Tahmasebi-Birgani M, Ansari H, Carloni V. Defective mitosis-linked DNA damage response and chromosomal instability in liver cancer[J]. Biochim Biophys Acta Rev Cancer, 2019, 1872(1): 60-65. DOI: 10.1016/j.bbcan.2019.05.008. doi:10.1016/j.bbcan.2019.05.008 |
| [1] | 陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349. |
| [2] | 许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363. |
| [3] | 彭琴, 蔡玉婷, 王伟.KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185. |
| [4] | 孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹.结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118. |
| [5] | 向玉玲, 谭佳杰, 熊远果, 赵丽蓉, 黎晨, 张洪.脱水淫羊藿素对肝癌细胞增殖、迁移和凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(9): 513-519. |
| [6] | 冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英.HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531. |
| [7] | 黄辉, 丁江华.靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573. |
| [8] | 王文德, 曾德.乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356. |
| [9] | 张丽, 向卓, 王强, 毕经旺.CAR-T免疫治疗相关的细胞因子释放综合征研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 377-381. |
| [10] | 丁浩, 应劲涛, 付茂勇.CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235. |
| [11] | 朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏.HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240. |
| [12] | 宁婷婷, 胡钦勇, 李倩, 杨鹏程.奥希替尼与埃克替尼一线治疗EGFR阳性转移性NSCLC临床疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 65-70. |
| [13] | 张碧霞, 丁江华.EGFR突变型非小细胞肺癌EGFR-TKI获得性耐药后免疫治疗现状[J]. 国际肿瘤学杂志, 2023, 50(2): 97-101. |
| [14] | 于晓鹏, 冯青青, 赵文飞, 赵文文, 魏红梅.靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635. |
| [15] | 许婷婷, 胡超苏, 李宝生.抗EGFR单抗治疗局部晚期头颈部鳞状细胞癌临床共识（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(1): 1-11. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||
